"Select the pharmaceutical enterprise with the strongest comprehensive R & D strength in your mind" is rushing into the field of chemical medicine. Who performs best?

The selection activity of "select the pharmaceutical enterprise with the strongest comprehensive R & D strength in your mind" launched by yaozhi.com and Southwest Securities is in hot progress Since 12:00 p.m on June 2, the activity has been officially launched In just five and a half days, the number of visitors has exceeded 1.9 million and the number of voters is about 180000 This activity not only attracted a large number of enterprises in the fields of traditional Chinese medicine and biology, but also actively participated by powerful pharmaceutical enterprises with great discourse power in the field of chemical pharmacy, which ushered in an unprecedented era For this reason, the small editors listed 10 enterprises that participated in the activity and had strong R & D strength in the field of chemical medicine They found that Huawei Pharmaceutical (currently more than 4000 votes) led the way, while other enterprises in the same field temporarily accompanied them As a big country of generic drugs, the development of generic drugs has been affecting the hearts of major R & D enterprises all over the country The new policy has been issued, and the State encourages new drug research and development Compared with other types of drug enterprises such as sales driven ones, R & D driven ones are in a good situation They have made great contributions to the development of the pharmaceutical industry, and they need everyone's approval to study day and night My friends, please move your golden fingers to let the "God of man" come to the stage from behind! 1 Hausen pharmaceutical: No.: 48 Founded in July 1995, Jiangsu Haosen Pharmaceutical Co., Ltd has developed into an innovative pharmaceutical group integrating chemical and biological drug research, pharmaceutical intermediates, API synthesis, preparation manufacturing and product sales It is the first key high-tech enterprise evaluated by the state, one of the top 100 pharmaceutical enterprises in China, and the largest anti-tumor and psychiatric drug research in China Development and production base At present, 217 varieties have been approved (in terms of acceptance number, the following is the same as above) Key products: gemcitabine hydrochloride for injection, zolpidem tartrate tablets, repaglinide metformin tablets, rabeprazole sodium enteric coated tablets, etibatide injection, moroxynidazole sodium chloride injection and other varieties 2 Hengrui pharmaceutical: No.: 52 Jiangsu Hengrui Pharmaceutical Co., Ltd is a large-scale pharmaceutical listed enterprise integrating scientific research, production and sales It is the largest research and production base of anti-tumor drugs in China The sales of anti-tumor drugs ranks first in China, with a market share of more than 12% It is a national designated manufacturer of narcotic drugs At present, 248 varieties have been approved Key products: mannitol, cefepime hydrochloride, cefotaxime sulfate, roxithromycin, ibuprofen, enalapril maleate and other varieties 3 Shiyao group: No.: 85 Shiyao Holding Group Co., Ltd is one of the leading enterprises in China's pharmaceutical industry, with a total assets of 20 billion yuan It is mainly engaged in the development, production and sales of medicine and related products, including seven series of nearly 1000 varieties, including antibiotics, vitamins, cardio cerebrovascular, antipyretic and analgesic, digestive system medicine, anti-tumor medicine and Chinese patent medicine At present, 165 varieties have been approved Key products: cefazolin sodium, cephalosporin esterase, map, l-phenylglycine, dunsyl salt, hydroxypropyl - β - cyclodextrin, 6-aminopenicillanic acid, Tongqiao deafness pill, etc 4 Huawei pharmaceutical: No.: 88 Nanjing Huawei Pharmaceutical Technology Co., Ltd (Huawei pharmaceutical) was founded in 2000 It is a high-tech enterprise specializing in drug discovery, research and technical services, focusing on anti-tumor, anti infection, gout, hypertension and diabetes At present, it has become a leading pharmaceutical R & D outsourcing service provider in the same industry in China, which can provide partners with full process services and integrated solutions from drug discovery, research, registration, clinical, CMO / API supply and other new drug development At present, 154 varieties have been approved Key products: ajidipine capsule, Prulifloxacin, pazufloxacin mesylate for injection, lanoconazole cream, zofenpril calcium capsule, etc 5 Kelun Pharmaceutical Co., Ltd.: No.: 89 Kelun group was founded in 1996 In 2015, the operating revenue of Kelun group exceeded 39 billion yuan and the profit and tax exceeded 2 billion yuan According to the 2012 sales ranking of China's pharmaceutical circulation industry and the annual report of the Ministry of industry and information technology on pharmaceutical statistics released by the Ministry of Commerce, the businesses and industries of Kelun group have both entered the top ten in China Production and sales include 579 varieties and 959 specifications of products including infusion, powder injection, freeze-dried powder injection, small water injection, tablet, capsule, granule, oral liquid, dialysate, API, medical packaging materials, medical devices, etc At present, 52 varieties have been approved Key products: glucose and sodium chloride injection, vitamin C and glucose injection, vinpocetine and glucose injection (shutongxin ®), compound mannitol injection (puke ®), antiviral drugs, hydroxyethyl starch 130 / 0.4 sodium chloride injection, etc 6 Qilu pharmaceutical: No.: 97 Qilu pharmaceutical was founded in 1958 The product section involves human medicine and agricultural and veterinary medicine The human medicine product involves the treatment drugs of difficult and multiple diseases such as tumor, anti infection, cardio cerebrovascular, spirit, nerve and ophthalmology It has the characteristics of "series, full dosage form, multi specification, large scale and high production capacity" At present, 226 varieties have been approved Key products: dicetabine for injection, citicoline sodium capsule, idebenone tablet, isosorbide monophosphate sustained-release tablet, clozapine tablet, mezlocillin sodium for injection and other varieties 7 Luoxin Pharmaceutical Co., Ltd.: No.: 109 Shandong Luoxin Pharmaceutical Group Co., Ltd was listed on Hong Kong H-share market in December 2005 At present, the company has three manufacturing bases, including more than 50 production lines, including powder injection, solid preparation (including cephalosporins), spray, large capacity injections, small volume injections, chemical raw materials, cephalosporins, and so on There are more than ten dosage forms and more than 300 product specifications, including 48 new China class drugs The company can produce 1 billion powder injections, 500 million freeze-dried powder injections, 400 million bottles (bags) of large capacity injections, 500 million small capacity injections, 7 billion tablets, 2 billion capsules and 300 million bags of granules annually At present, 208 varieties have been approved Key products: aztreonam for roti ® injection, cefuroxime sodium, omeprazole enteric coated capsules for Rodin ® injection, cefmendor doxetil sodium for Liyuan ® injection, meclofene hydrochloride for injection, etc 8 Haizheng Pharmaceutical Co., Ltd.: No.: 110 was founded in 1956 in Zhejiang Haizheng Pharmaceutical Co., Ltd., which is one of the largest production bases of antibiotics and anti-tumor drugs in China Adhering to the mission of "persisting in drug innovation and achieving health dream" and the vision of "becoming a well respected global pharmaceutical enterprise", we are committed to integrating drug R & D and production resources and providing better products and services for global customers More than 40 varieties have been officially certified by FDA, EDQM of EU, TGA of Australia, KFDA of South Korea, and sold to more than 30 countries and regions around the world District At present, 144 varieties have been approved Key products: recombinant human tumor necrosis factor receptor antibody fusion protein for injection, tegacyclin, cycloserine capsule, bicalutamide, tacrolimus and other varieties 9 Fosun Pharmaceutical: No.: 116 Shanghai Fosun Pharmaceutical (Group) Co., Ltd (hereinafter referred to as "Fosun Pharmaceutical") was founded in 1994 and listed in 1998 R & D of the company focuses on cardiovascular, anti-tumor, central nervous system, blood system, metabolism, digestive tract and anti infection treatment fields Key products: split vaccine of influenza A H1N1 virus, recombinant human erythropoietin for injection (CHO cell), reduced glutathione preparation, low molecular weight heparin sodium for injection, meglumine cyclophosphate injection, etc 10 Zhengda Tianqing: No.: 117 Zhengda Tianqing Pharmaceutical Group is an innovative pharmaceutical group enterprise integrating scientific research, production and sales It is the largest R & D and production base of liver health drugs in China The treatment of Zhengda Tianqing products involves liver disease, tumor, respiration, infection, digestion and other diseases Ten products with an annual sales of more than 100 million yuan form a "hundred million yuan product group", among which 2 billion yuan products are sold annually Two of them are the national first-class new drug isoglycyrrhizic acid magnesium injection (Tianqing Ganmei) and the first listed entecavir dispersible tablet (Runzhong) At present, 196 varieties have been approved Key products: isoglycyrrhizic acid magnesium injection (Tianqing Ganmei), entecavir dispersible tablets (Runzhong), adefovir dipivoxil capsule (Mingzheng), desetabine, imatinib, dasatinib and other varieties Note: the content of this article is original by the author of yaozhi.com Please indicate the source and the author's name when reprinting Thank you!